Future directions for monitoring treatment responses in breast cancer

Journal of Cancer

Volumn 5, Issue 1, 2014, Pages 69-78

  Shupe, Matthew P ^a   Graham, Lindsey J ^a   Schneble, Erika J ^a   Flynt, Frederick L ^a   Clemenshaw, Michael N ^a   Kirkpatrick, Aaron D ^a   Stojadinovic, Alexander ^b   Peoples, George E ^c   Shumway, Nathan M ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Adjuvant; breast cancer; Future directions; Metastatic; Neoadjuvant; Treatment monitoring

Indexed keywords

CARBOPLATIN; CYTOTOXIC AGENT; ERIBULIN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

AXILLARY LYMPH NODE; BIOLOGICAL MONITORING; BREAST CANCER; CANCER ADJUVANT THERAPY; CIRCULATING TUMOR CELL; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); HEALTH CARE QUALITY; HUMAN; MEDICAL TECHNOLOGY; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; POSTOPERATIVE COMPLICATION; REVIEW; TREATMENT RESPONSE;

EID: 84893635159     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.7048     Document Type: Review

References (62)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62: 220-41. doi:10.3322/caac.21149.
2. Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA. 2013; 309: 800-5. doi:10.1001/jama.2013.776.
3. Menes TS, Tartter PI, Bleiweiss I, Godbold JH, Estabrook A, Smith SR. The consequence of multiple re-excisions to obtain clear lumpectomy margins in breast cancer patients. Annals of Surgical Oncology. 2005; 12: 881-5. doi:Doi 10.1245/Aso.2005.03.021.
4. Mullenix PS, Cuadrado DG, Steele SR, Martin MJ, See CS, Beitler AL, et al. Secondary operations are frequently required to complete the surgical phase of therapy in the era of breast conservation and sentinel lymph node biopsy. American Journal of Surgery. 2004; 187: 643-6. doi:DOI 10.1016/j.amjsurg.2004.01.003.
5. Chen K, Zeng Y, Jia H, Jia W, Yang H, Rao N, et al. Clinical outcomes of breast-conserving surgery in patients using a modified method for cavity margin assessment. Ann Surg Oncol. 2012; 19: 3386-94. doi:10.1245/s10434-012-2331-5.
6. Jacobson AF, Asad J, Boolbol SK, Osborne MP, Boachie-Adjei K, Feldman SM. Do additional shaved margins at the time of lumpectomy eliminate the need for re-excision? Am J Surg. 2008; 196: 556-8. doi:10.1016/j.amjsurg.2008.06.007.
7. Janes SE, Stankhe M, Singh S, Isgar B. Systematic cavity shaves reduces close margins and re-excision rates in breast conserving surgery. Breast. 2006; 15: 326-30. doi:10.1016/j.breast.2005.10.006.
8. Feron JG, Nguyen A, Bezu C, Antoine M, Darai E, Coutant C, et al. Interest in cavity shaving in breast conservative treatment does not depend on lumpectomy technique. Breast. 2011; 20: 358-64. doi:10.1016/j.breast.2011.01.014.
9. Klimberg VS, Harms S, Korourian S. Assessing margin status. Surg Oncol. 1999; 8: 77-84. doi:S0960-7404(99)00031-6 [pii].
10. Pappo I, Spector R, Schindel A, Morgenstern S, Sandbank J, Leider LT, et al. Diagnostic performance of a novel device for real-time margin assessment in lumpectomy specimens. J Surg Res. 2010; 160: 277-81. doi:10.1016/j.jss.2009.02.025.
11. Allweis TM, Kaufman Z, Lelcuk S, Pappo I, Karni T, Schneebaum S, et al. A prospective, randomized, controlled, multicenter study of a real-time, intraoperative probe for positive margin detection in breast-conserving surgery. Am J Surg. 2008; 196: 483-9. doi:10.1016/j.amjsurg.2008.06.024.
12. Bathla L, Harris A, Davey M, Sharma P, Silva E. High resolution intra-operative two-dimensional specimen mammography and its impact on second operation for re-excision of positive margins at final pathology after breast conservation surgery. Am J Surg. 2011; 202: 387-94. doi:10.1016/j.amjsurg.2010.09.031.
13. Kaufman CS, Jacobson L, Bachman BA, Kaufman LB, Mahon C, Gambrell LJ, et al. Intraoperative digital specimen mammography: rapid, accurate results expedite surgery. Ann Surg Oncol. 2007; 14: 1478-85. doi:10.1245/s10434-006-9126-5.
14. Chagpar A, Yen T, Sahin A, Hunt KK, Whitman GJ, Ames FC, et al. Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. Am J Surg. 2003; 186: 371-7. doi:S0002961003002642 [pii].
15. Graham RA, Homer MJ, Sigler CJ, Safaii H, Schmid CH, Marchant DJ, et al. The efficacy of specimen radiography in evaluating the surgical margins of impalpable breast carcinoma. AJR Am J Roentgenol. 1994; 162: 33-6. doi:10.2214/ajr.162.1.8273685.
16. Tang R, Buckley JM, Fernandez L, Coopey S, Aftreth O, Michaelson J, et al. Micro-computed tomography (Micro-CT): a novel approach for intraoperative breast cancer specimen imaging. Breast Cancer Res Treat. 2013; 139: 311-6. doi:10.1007/s10549-013-2554-6.
17. Gufler H, Franke FE, Wagner S, Rau WS. Fine structure of breast tissue on micro computed tomography a feasibility study. Acad Radiol. 2011; 18: 230-4. doi:10.1016/j.acra.2010.10.006.
18. Gurtner GC, Jones GE, Neligan PC, Newman MI, Phillips BT, Sacks JM, et al. Intraoperative laser angiography using the SPY system: review of the literature and recommendations for use. Ann Surg Innov Res. 2013; 7: 1. doi:10.1186/1750-1164-7-1.
19. Newman MI, Jack MC, Samson MC. SPY-Q analysis toolkit values potentially predict mastectomy flap necrosis. Ann Plast Surg. 2013; 70: 595-8. doi:10.1097/SAP.0b013e3182650b4e.
20. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011; 305: 569-75. doi:10.1001/jama.2011.90.
21. Milgrom S, Cody H, Tan L, Morrow M, Pesce C, Setton J, et al. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment. Ann Surg Oncol. 2012; 19: 3762-70. doi:10.1245/s10434-012-2386-3.
22. Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010; 17 Suppl 3: 343-51. doi:10.1245/s10434-010-1253-3.
23. Arasu VA, Joe BN, LvoffNM, Leung JW, Brenner RJ, Flowers CI, et al. Benefit of semiannual ipsilateral mammographic surveillance following breast conservation therapy. Radiology. 2012; 264: 371-7. doi:10.1148/radiol.12111458.
24. Hakim CM, Chough DM, Ganott MA, Sumkin JH, Zuley ML, Gur D. Digital breast tomosynthesis in the diagnostic environment: A subjective side-by-side review. AJR Am J Roentgenol. 2010; 195: W172-6. doi:10.2214/AJR.09.3244.
25. Noroozian M, Hadjiiski L, Rahnama-Moghadam S, Klein KA, Jeffries DO, Pinsky RW, et al. Digital breast tomosynthesis is comparable to mammographic spot views for mass characterization. Radiology. 2012; 262: 61-8. doi:10.1148/radiol.11101763.
26. Skaane P, Gullien R, Bjorndal H, Eben EB, Ekseth U, Haakenaasen U, et al. Digital breast tomosynthesis (DBT): initial experience in a clinical setting. Acta Radiol. 2012; 53: 524-9. doi:10.1258/ar.2012.120062.
27. Drukteinis JS, Mooney BP, Flowers CI, Gatenby RA. Beyond mammography: new frontiers in breast cancer screening. Am J Med. 2013; 126: 472-9. doi:10.1016/j.amjmed.2012.11.025.
28. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of Clinical Oncology. 1998; 16: 2672-85.
29. Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, et al. Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat. 2010; 124: 723-32. doi:10.1007/s10549-010-1181-8.
30. Chen YZ, Xue JY, Chen CM, Yang BL, Xu QH, Wu F, et al. PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy. Cancer Chemother Pharmacol. 2012; 70: 637-44. doi:10.1007/s00280-012-1949-0.
31. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 2008; 19: 1847-52. doi:10.1093/annonc/mdn395.
32. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367: 1783-91. doi:10.1056/NEJMoa1209124.
33. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50 Suppl 1: 122S-50S. doi:10.2967/jnumed.108.057307.
34. Skougaard K, Nielsen D, Jensen BV, Hendel HW. Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab. J Nucl Med. 2013. doi:10.2967/jnumed.112.111757.
35. Hamaoka T, Madewell JE, PodoloffDA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004; 22: 2942-53. doi:10.1200/JCO.2004.08.181.
36. Hatt M, Groheux D, Martineau A, Espie M, Hindie E, Giacchetti S, et al. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med. 2013; 54: 341-9. doi:10.2967/jnumed.112.108837.
37. Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010; 1: 80-92.
38. Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, et al. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 2010; 102: 651-7. doi:10.1038/sj.bjc.6605546.
39. Khokher S, Qureshi MU, Chaudhry NA. Comparison of WHO and RECIST criteria for evaluation of clinical response to chemotherapy in patients with advanced breast cancer. Asian Pac J Cancer Prev. 2012; 13: 3213-8.
40. Peterson LM, MankoffDA, Lawton T, Yagle K, Schubert EK, Stekhova S, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med. 2008; 49: 367-74. doi:10.2967/jnumed.107.047506.
41. van Kruchten M, Glaudemans AW, de Vries EF, Beets-Tan RG, Schroder CP, Dierckx RA, et al. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med. 2012; 53: 182-90. doi:10.2967/jnumed.111.092734.
42. Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013; 22: 203-10. doi:10.1016/j.breast.2013.03.006.
43. Hayes DF, Bast RC, Desch CE, Fritsche H, Jr., Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996; 88: 1456-66.
44. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005; 93: 387-91. doi:10.1038/sj.bjc.6602678.
45. Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist. 2006; 11: 541-52. doi:10.1634/theoncologist.11-6-541.
46. Mirza NQ, Vlastos G, Meric F, Buchholz TA, Esnaola N, Singletary SE, et al. Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Ann Surg Oncol. 2002; 9: 256-65.
47. Cristofanilli M. The biological information obtainable from circulating tumor cells. Breast. 2009; 18 Suppl 3: S38-40. doi:10.1016/S0960-9776(09)70270-X.
48. Ntoulia M, Stathopoulou A, Ignatiadis M, Malamos N, Mavroudis D, Georgoulias V, et al. Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Clin Biochem. 2006; 39: 879-87. doi:10.1016/j.clinbiochem.2006.06.009.
49. Benoy IH, Elst H, Van der Auwera I, Van Laere S, van Dam P, Van Marck E, et al. Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. Br J Cancer. 2004; 91: 1813-20. doi:10.1038/sj.bjc.6602189.
50. Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, Stathopoulos E, et al. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer. 2009; 101: 589-97. doi:10.1038/sj.bjc.6605183.
51. Pierga JY, Bidard FC, Denis MG, de Cremoux P. Prognostic value of peripheral blood double detection of CK19 and MUC1 mRNA positive cells detected by RT-quantitative PCR in 94 breast cancer patients with a follow up of 9 years. Mol Oncol. 2007; 1: 267-8. doi:10.1016/j.molonc.2007.09.005.
52. Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol. 2010; 21: 729-33. doi:10.1093/annonc/mdp391.
53. Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 2008; 14: 7004-10. doi:10.1158/1078-0432.CCR-08-0030.
54. Payne RE, Yague E, Slade MJ, Apostolopoulos C, Jiao LR, Ward B, et al. Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics. 2009; 10: 51-7. doi:10.2217/14622416.10.1.51.
55. Muller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System and AdnaTest Breast in metastatic breast cancer patients: the DETECT study. Breast Cancer Res. 2012; 14: R118. doi:10.1186/bcr3243.
56. Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex CellSearch system. Int J Cancer. 2012; 130: 1590-7. doi:10.1002/ijc.26111.
57. Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol. 2009; 27: 1685-93. doi:10.1200/JCO.2008.16.8351.
58. Kostler WJ, Schwab B, Singer CF, Neumann R, Rucklinger E, Brodowicz T, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004; 10: 1618-24.
59. Tse C, Gauchez AS, Jacot W, Lamy PJ. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev. 2012; 38: 133-42. doi:10.1016/j.ctrv.2011.03.008.
60. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368: 1199-209. doi:10.1056/NEJMoa1213261.
61. Zurita M, Lara PC, del Moral R, Torres B, Linares-Fernandez JL, Arrabal SR, et al. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC Cancer. 2010; 10: 217. doi:10.1186/1471-2407-10-217.
62. Fan J, Deng X, Gallagher JW, Huang H, Huang Y, Wen J, et al. Monitoring the progression of metastatic breast cancer on nanoporous silica chips. Philos Trans A Math Phys Eng Sci. 2012; 370: 2433-47. doi:10.1098/rsta.2011.0444.